Zhao Qing-Tao, Yang Yong, Xu Shun, Zhang Xiao-Peng, Wang Hui-En, Zhang Hua, Wang Zhi-Kang, Yuan Zheng, Duan Guo-Chen
Department of Thoracic Surgery, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China.
Department of General Surgery, Sujiatun Central Hospital, China Medical University, Shenyang, Liaoning, People's Republic of China.
Onco Targets Ther. 2015 Sep 29;8:2731-8. doi: 10.2147/OTT.S90875. eCollection 2015.
Neutrophil to lymphocyte ratio (NLR) has recently been reported to be a poor prognostic indicator in lung cancer. However, the prognostic value of the NLR in patients with lung cancer still remains controversial. We performed a meta-analysis to evaluate the prognostic value of NLR in patients with lung cancer.
We performed a comprehensive literature search in PubMed, Ovid, the Cochrane Library, and Web of Science databases in May 2015. Studies were assessed for quality using the Newcastle-Ottawa Scale.
Twenty-two studies with a total of 7,054 patients were included in this meta-analysis. The meta-analysis was performed to generate combined hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS). Our analysis results indicated that high NLR predicted poorer OS (HR, 1.51; 95% confidence interval [CI], 1.33-1.71; P<0.001) and PFS (HR, 1.33; 95% CI, 1.07-1.67; P=0.012) in patients with lung cancer. High NLR was also associated with poor OS in lung cancer treated by surgical resection (HR, 1.59; 95% CI, 1.26-1.99; P<0.001) and chemotherapy (HR, 1.15; 95% CI, 1.08-1.22; P<0.001). In addition, NLR cut-off value =5 (HR, 1.57; 95% CI, 1.16-2.12; P=0.003) and NLR cut-off value <5 (HR, 1.47; 95% CI, 1.28-1.69; P<0.001).
This meta-analysis result suggested that NLR should have significant predictive ability for estimating OS and PFS in patients with lung cancer and may be as a significant biomarker in the prognosis of lung cancer.
中性粒细胞与淋巴细胞比值(NLR)最近被报道为肺癌预后不良的指标。然而,NLR在肺癌患者中的预后价值仍存在争议。我们进行了一项荟萃分析,以评估NLR在肺癌患者中的预后价值。
2015年5月,我们在PubMed、Ovid、Cochrane图书馆和Web of Science数据库中进行了全面的文献检索。使用纽卡斯尔-渥太华量表评估研究质量。
本荟萃分析纳入了22项研究,共7054例患者。进行荟萃分析以生成总生存期(OS)和无进展生存期(PFS)的合并风险比(HR)。我们的分析结果表明,高NLR预示肺癌患者的OS较差(HR,1.51;95%置信区间[CI],1.33 - 1.71;P<0.001)和PFS较差(HR,1.33;95% CI,1.07 - 1.67;P = 0.012)。高NLR也与手术切除(HR,1.59;95% CI,1.26 - 1.99;P<0.001)和化疗(HR,1.15;95% CI,1.08 - 1.22;P<0.001)治疗的肺癌患者的OS较差相关。此外,NLR临界值 = 5(HR,1.57;95% CI,1.16 - 2.12;P = 0.003)和NLR临界值<5(HR,1.47;95% CI,1.28 - 1.69;P<0.001)。
这项荟萃分析结果表明,NLR在估计肺癌患者的OS和PFS方面应具有显著的预测能力,并且可能作为肺癌预后的重要生物标志物。